CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best stocks under $5 with highest upside potential. On October 28, Oppenheimer analyst Matthew Biegler maintained a Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and set a$7 price target. However, J.P. Morgan analyst Anupam Rama reiterated a Hold rating on the stock on October 23 without assigning a price target. Rama based the rating on the future potential and current status of CytomX Therapeutics’ CX-2051, stating that he expects more cla ...